Status:
COMPLETED
Investigating the Anti-inflammatory Effects of Frondanol in Adults With Inflammatory Bowel Disease
Lead Sponsor:
Mohammed Bin Rashid University of Medicine and Health Sciences
Collaborating Sponsors:
Mediclinic Middle East
Rashid Hospital
Conditions:
Ulcerative Colitis Chronic Mild
Ulcerative Colitis Chronic Moderate
Eligibility:
All Genders
18+ years
Phase:
PHASE2
PHASE3
Brief Summary
This is a pilot, prospective, double-blinded, two-arm, randomized controlled trial of the efficacy of Frondanol in comparison to placebo in decreasing bowel inflammation in patients with a clinical di...
Detailed Description
Inflammatory bowel disease (IBD), consisting of Crohn's disease and ulcerative colitis, is a debilitating condition, particularly during active periods (flares) of the disease and can sometimes lead t...
Eligibility Criteria
Inclusion
- Inclusion criteria:
- A confirmed clinical diagnosis of IBD of any duration, age 18 years or older, with mild to moderate disease and on standard therapy.
- The diagnostic criteria for IBD include the presence of chronic diarrhea for more than four weeks, and evidence of active inflammation on endoscopy and chronic changes on biopsy.
- Patients with stable mild to moderate IBD will be eligible for the study.
- Stable IBD is defined as having stable symptoms over a period of several weeks, diagnostic evaluation has been completed and the patient has been on consistent medication.
- Mild to moderate IBD is indicated by a Partial Mayo score (Mayo Clinic Score/Disease Activity Index for Colitis) of between 1-6, and a total of Mayo score of 1-10.
- For patients with Crohn's disease, only those with Crohn's colitis will be included (patients with small bowel disease are eligible to enter the trial as long as they also have large bowel inflammation).
- Exclusion criteria:
- Pregnancy, breastfeeding, allergy to seafood or marine products
- Severe medical illness such as uncontrolled diabetes (HbA1C\>10), significant or unstable cardiovascular or pulmonary disease, impaired renal function (Cr\>2.0mg/dL), current or recent (\<1 year) malignancy, or other significant medical illness that in the view of the investigators may impair participation in the study.
- Patients with severe IBD (defined by a Partial Mayo score of 7-9 and a total Mayo score of 11-12, with active symptoms) will not be eligible to participate in the study.
Exclusion
Key Trial Info
Start Date :
February 19 2022
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 19 2024
Estimated Enrollment :
13 Patients enrolled
Trial Details
Trial ID
NCT05194007
Start Date
February 19 2022
End Date
November 19 2024
Last Update
November 20 2024
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Mediclinic City Hospital
Dubai, United Arab Emirates
2
Mediclinic Parkview Hospital
Dubai, United Arab Emirates